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Data on stem cell transplantation (SCT) for DiamondBlackfan Anemia (DBA) is limited. We studied patients
transplanted for DBA and registered in the EBMT database. Between 1985 and 2016, 106 DBA patients (median
age, 6.8 years) underwent hematopoietic stem cell transplantation from matched-sibling donors (57%), unrelated
donors (36%), or other related donors (7%), using marrow (68%), peripheral blood stem cells (20%), both marrow
and peripheral blood stem cells (1%), or cord blood (11%). The cumulative incidence of engraftment was 86% (80%
to 93%), and neutrophil recovery and platelet recovery were achieved on day +18 (range, 16 to 20) and +36 (range,
32 to 43), respectively. Three-year overall survival and event-free survival were 84% (77% to 91%) and 81% (74% to
89%), respectively. Older patients were significantly more likely to die (hazard ratio, 1.4; 95% confidence interval,
1.06 to 1.23; P < .001). Outcomes were similar between sibling compared to unrelated-donor transplants. The
incidence of acute grades II to IV of graft-versus-host disease (GVHD) was 30% (21% to 39%), and the incidence of
extensive chronic GVHD was 15% (7% to 22%). This study shows that SCT may represent an alternative therapeutic
option for transfusion-dependent younger patients.





DiamondBlackfan anemia (DBA) is a congenital pure
red cell aplasia, secondary to genetic defects of ribosomal
proteins. It usually, but not exclusively, presents within the
first year of life and can be associated with congenital
abnormalities, as well as increased risk for cancer, mostly
solid tumors. Some patients are successfully treated with
steroids, but many of them remain dependent with unac-
ceptable side effects, or they do not respond. Hematopoi-
etic stem cell transplantation (HSCT) represents the only
curative option for the hematological features of this dis-
ease. The reported studies show an improvement in overall
survival (OS) over time (45% to 91%) that was more evident
in unrelated donors as the source of stem cells, such that
OS increased from 19% to 92% [1-5]. The same studies
show better results in patients younger than 10 years of
age and transplanted after the year 2000. In this retrospec-
tive study, we describe the outcomes of HSCT of the largest
reported cohort of patients with DBA included in the
EBMT database.
PATIENTS ANDMETHODS
Data from patients of any age who underwent HSCT for DBA
between 1985 and 2016 and were registered in the EBMT database were
analyzed. Details on transplant procedures were obtained from the data-
base, and the patients’ clinical information was collected by a specific
disease-oriented questionnaire distributed to the participating centers.
Engraftment was defined as the first date of a neutrophil count 
0.5£ 109/L for at least 3 consecutive days. Primary and secondary graft
failure were defined as neutrophil count never reaching 0.5£ 109/L and
as a decrease in their count to a lower level after initial engraftment,
respectively. Iron overload was defined as ferritin serum level >
1000 mg/dL and/or the presence of pathological liver iron concentration
by magnetic resonance imaging.
The overall survival (OS) and event-free survival (EFS), defined as survival
without graft loss, relapse, malignancy, or a second transplant, were calcu-
lated using the KaplanMeier product limit estimation method; differences
in subgroups were assessed by the log-rank test. The reverse KaplanMeier
method was used to estimate the median follow-up. Cumulative incidences
of acute graft-versus-host disease (aGVHD), chronic graft versus host disease
(cGVHD), and graft failure were analyzed separately in a competing risks
framework, and subgroup differences were assessed by Gray’s test.Competing events for graft failure and acute or chronic GVHD included sec-
ond transplant, relapse, and death. In the corresponding figures, failure from
any competing event is referred to simply as “failure.” All estimates were
reported with a corresponding 95% confidence interval (CI), and P < .05 was
considered significant.RESULTS AND DISCUSSION
Between 1985 and 2016, 106 patients (60 males, 57%; 46
females, 43%; mean age, 6.8 years; interquartile range [IQR], 3.7
to 11.2) underwent HSCT. Congenital malformations were pres-
ent in 62% of patients. At the time of stem cell transplantation
(SCT), patients had undergone a number of red blood cells
transfusions: <20 (38% of cases) and >20 (62% of cases). Iron
overload was present in 77% of patients, and previous treat-
ments included steroids (93%), erythropoietin (11%), and leu-
cine (5%). Transfusion dependency, iron overload, and evolution
to aplasia represented the most common indications to trans-
plant in 70%, 15%, and 7% of cases, respectively. Median hemo-
globin, neutrophils, and platelet counts at SCT were 9.1 g/dL
(IQR, 8 to 10.2), 1.8£ 103/mL (IQR, 1.3 to 2.9), and 285£ 103/mL
(IQR, 147 to 353), respectively. Patient characteristics and trans-
plant features are provided in Table 1. Median days to neutro-
phil and platelet engraftment were 18 (range, 16 to 20) and 36
(range, 32 to 43), respectively. Median follow-up was 68
months (range, 52 to 89). EFS and OS at 36 months were 81%
(range, 74% to 89%) and 84% (range, 77% to 91%), respectively
(Figure 1). Older patients were significantly more likely to die
(hazard ratio [HR], 1.4; 95% CI, 1.06 to 1.23; P< .001). No signifi-
cant differences on outcome were noted based on the year of
transplant or the type of conditioning regimen. The median
incidence of day 100 aGVHD (grades II to IV) was 30% (range,
21% to 39%), and the median incidence of extensive cGVHD at
36 months was 15% (range, 7% to 22%). Although not statisti-
cally significant, a higher incidence of extensive cGVHD was
present in patients transplanted from unrelated donors (median
23%; range, 8% to 38%) compared to those who received stem
cells from siblings (median 11%; range, 3% to 20%). Also associ-
ated with a significantly higher incidence of extensive cGVHD
Table 1
Patient and Transplant Characteristics
Characteristic Value
Status at SCT
Ferritin levels (ng/mL), median (IQR) 1272 (8562230)
Age (yr), median (range) 6.8 ( 1-32)
Years of SCT, n (%)
19852010 56 (53)
20112016 50 (47)
Donor type (missing 4), n (%)
Identical sibling 58 (57)
Unrelated donor 37 (36)
Other relative 7 (7)










Stem cell source, n (%)
Bone marrow 68 (64)
Peripheral blood 21 (20)
Cord blood 16 (15)
Bone marrow and peripheral blood 1 (1)
GVHD prophylaxis (missing 10), n
Cyclosporin +MTX § other 52























Aplasia, not evaluated, or lost engraftment 5
Missing 17
CMV indicates cytomegalovirus; MTX, methotrexate; MMF, mycophenolate
mofetil.
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(P = .04) and number of previous red blood cell transfusions
(<20 units, 4%; range, 0% to 12% versus 20 units, 24%; range,
11% to 36%) (P= .05) (Figure 1).Sixteen patients died during follow-up due to infections
(n = 7), GVHD (n = 4), organ failure (n = 2), other transplant-
related causes (n = 2), or unknown causes (n = 1). Seven
patients developed secondary malignancies (two solid tumors,
one myelodysplasia, one non-Hodgkin lymphoma, two
unknown) at a median of 67 months from HSCT
To the best of our knowledge, this is the largest reported
cohort of patients transplanted for DBA, and it represents a signif-
icant number of cases reported after 2010 that show very good
OS in patients< 10 years of age, independent of donor type.
The better outcome of younger children, already shown in
previous reports [4], has been confirmed in this much larger
cohort of patients, highlighting the importance of identifying
the correct timing to undergo transplantation in the manage-
ment of transfusion-dependent patients with DBA, especially
considering that the desired outcomes continuously reduce
with age. In fact, an earlier procedure may prevent the iron
overload side-effects that are known to predispose to greater
transplant-related toxicity [6]. Indeed, previous reports on
patients transplanted for other disorders requiring regular
transfusions, such as thalassemia or congenital dyserythro-
poietic anemia [7,8], have already shown that tissue damage
secondary to iron overload greatly impairs the outcome.
Although in our study the number of red blood cell transfu-
sions and presence of iron overload did not have any impact
on survival, they were significantly associated with a higher
incidence of extensive cGVHD, suggesting that adequate chela-
tion treatment during early phases of the disease and complete
evaluation of iron overload before transplant are mandatory in
patients with DBA.
It is worth noting that the good outcomes of DBA patients
transplanted under the age of 10 years must be viewed with
caution and might not represent an absolute indication per se
for HSCT. Unfortunately, sufficient outcome data on patients
regularly transfused and correctly chelated who did not
receive a transplant are not available to compare with those
undertaking HSCT. Indeed, according to the North American
DBA Registry, OS at age greater than 40 years is 75% [3], and
these results might be even higher in the future due to the
improvement of supportive therapies and chelation treat-
ments seen over the last few years. Moreover, in the setting of
other constitutional marrow failure syndromes such as Fan-
coni anemia, the management of which also highlights the
dilemma regarding the timing of transplantation, it has been
shown that, for moderate cytopenia, the OS of transplanted
and non-transplanted patients is similar [9]. This finding rein-
forces the fact that indication and the timing for HSCT in DBA
patients may not be dictated by age per se but instead should
be carefully weighted and tailored according to the status of
each patient. The possibility of correcting the hemopoietic
manifestations of the disease must be balanced against the
risk of cGVHD, which, in another transfusion-dependent ane-
mia such as thalassaemia, is known to be associated with a
lack of normalization of quality of life [10], and it is possible
that conditioning may exacerbate the risk of tumors.
Our study did not show any difference in terms of survival
between transplants from siblings or unrelated donors, con-
firming the trend of improving outcomes over the years
[2,3,5], which was clearly highlighted in a recent study on a
German and French cohort of children and adolescents whose
OS was > 90% [5]. In our cohort of patients, which also
included adult patients, mostly transplanted after 2010, OS
and EFS were both higher (>80%), independently of donor
type. The good outcome of unrelated donor transplants is par-
ticularly important for congenital diseases, which reduce the
Figure 1. (A) EFS and OS. (B) EFS according to age. (C) OS according to age. (D) EFS according to donor type. (E) OS according to donor type. (F) Incidence of aGVHD. (G)
Incidence of cGVHD. (H) Incidence of extensive cGVHD according to iron overload. (I) Incidence of extensive cGVHD according to number of transfusions. Failure indi-
cates failure from any competing event
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[8,11]. No significant differences were observed in OS by the
type of stem cell source and conditioning regimen. Although
previous reports have demonstrated that patients transplanted
using cord blood had inferior outcomes [4,12], we did not
observe any difference, although this may have been due to
the small numbers.
More than 80% of patients underwent either a busulfan- or
a treosulfan-based myeloablative conditioning regimen.
Although in our study there was no significant difference with
other regimens, these approaches and, in particular, the use of
the less toxic drug treosulfan have recently been recom-
mended by an international expert panel [13] and can repre-
sent a balanced choice to reduce transplant-related toxicity
while maintaining a high engraftment rate. Treosulfan is par-
ticularly useful in constitutional marrow failure syndromes
[1416] that bear an intrinsic predisposition to malignancies,
as is the case for DBA, which has a cumulative incidence of 20%
by the age of 46 years [17], mostly due to solid tumors. In our
cohort, 6% of patients developed post-transplant malignancies,
and this figure is likely to further increase with follow-up
time. Therefore, the use of a treosulfan-based conditioning
regimen would be preferable in DBA patients, due to its
reduced toxic effects.
In conclusion, the very good OS of patients undergoing
transplant from both sibling and unrelated donors and theacceptable rate of cGVHD confirm that this procedure can be
considered as an alternative option for young transfusion-
dependent patients, after careful evaluation of patient-specific
issues and needs.ACKNOWLEDGMENTS
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